MIRV is named as a drug or biological intervention in 3 clinical trials in our China, Ireland, UK, USA and India trial registers, 2 of which are recruiting. Lead sponsors include AstraZeneca (1), Eli Lilly and Company (1) and Fudan University (1). Registered phases: Phase 3 and Phase 2. Conditions studied include Epithelial Ovarian Cancer; Ovarian Neoplasms; Fallopian Tube Neoplasms.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07213804 | A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer (ClinicalTrials.gov ↗) Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms |
Phase 3 | Recruiting |
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer Epithelial Ovarian Cancer |
Phase 3 | Recruiting |
| NCT07825753 | Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer (ClinicalTrials.gov ↗) Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC) |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Epithelial Ovarian Cancer | 1 |
| Ovarian Neoplasms | 1 |
| Fallopian Tube Neoplasms | 1 |
| Peritoneal Neoplasms | 1 |
| Neoplasm Metastasis | 1 |
| Advanced or Metastatic Pancreatic Adenocarcinoma | 1 |
| Advanced or Metastatic Breast Cancer (BC) | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 1 |
| Eli Lilly and Company | 1 |
| Fudan University | 1 |
| Register | MIRV trials |
|---|---|
| Clinical trials in China | 3 |
| Clinical trials in Ireland | 2 |
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how MIRV works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MIRV (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.